{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:53:46Z","timestamp":1793840026665,"version":"4.6.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"29","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T00:00:00Z","timestamp":1531958400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/open-government-licence\/version\/3\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.vaccine.2018.06.038","type":"journal-article","created":{"date-parts":[[2018,12,10]],"date-time":"2018-12-10T02:15:15Z","timestamp":1544408115000},"page":"3747-3753","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Development and validation of a monocyte activation test for the control\/safety testing of an OMV-based meningococcal B vaccine"],"prefix":"10.1016","volume":"37","author":[{"given":"Caroline","family":"Vipond","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Sutherland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Nordgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Kemp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Heath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory","family":"Care","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Studholme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.06.038_b0005","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jim.2005.01.010","article-title":"International validation of novel pyrogen tests based on human monocytoid cells","volume":"298","author":"Hoffmann","year":"2005","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2018.06.038_b0010","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1128\/aem.36.3.445-449.1978","article-title":"Endotoxins in commercial vaccines","volume":"36","author":"Geier","year":"1978","journal-title":"Appl Environ Microbiol"},{"key":"10.1016\/j.vaccine.2018.06.038_b0015","doi-asserted-by":"crossref","first-page":"47","DOI":"10.14573\/altex.1509291","article-title":"Limitations of the rabbit pyrogen test for assessing meningococcal OMV based vaccines","volume":"33","author":"Vipond","year":"2016","journal-title":"ALTEX"},{"key":"10.1016\/j.vaccine.2018.06.038_b0020","first-page":"323","article-title":"Effect of aluminium hydroxide and meningococcal serogroup C capsular polysaccharide on the immunogenicity and reactogenicity of a group B Neisseria meningitidis outer membrane vesicle vaccine","volume":"92","author":"Rosenqvist","year":"1998","journal-title":"Dev Biol Stand"},{"key":"10.1016\/j.vaccine.2018.06.038_b0025","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1093\/infdis\/137.6.728","article-title":"Safety and immunogenicity of a Neisseria meningitidis Type 2 protein vaccine in animals and humans","volume":"137","author":"Zollinger","year":"1978","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.06.038_b0030","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1128\/iai.37.1.271-280.1982","article-title":"Protection against group B Neisseria meningitidis disease: preparation of soluble protein and protein-polysaccharide immunogens","volume":"37","author":"Frasch","year":"1982","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.06.038_b0035","first-page":"325","article-title":"A bacterial disease of Limulus polyphemus","volume":"98","author":"Bang","year":"1956","journal-title":"Bull Johns Hopkins Hosp"},{"key":"10.1016\/j.vaccine.2018.06.038_b0040","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/0140-6736(91)91961-S","article-title":"Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway","volume":"338","author":"Bjune","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.06.038_b0045","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/0140-6736(92)93086-3","article-title":"Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil","volume":"340","author":"de Moraes","year":"1992","journal-title":"Lance."},{"key":"10.1016\/j.vaccine.2018.06.038_b0050","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1016\/j.vaccine.2005.01.063","article-title":"MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain","volume":"23","author":"Oster","year":"2005","journal-title":"Vaccine."},{"issue":"2","key":"10.1016\/j.vaccine.2018.06.038_b0055","first-page":"195","article-title":"Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba","volume":"14","author":"Sierra","year":"1991","journal-title":"NIPH Ann"},{"key":"10.1016\/j.vaccine.2018.06.038_b0060","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1002\/pmic.200500821","article-title":"Proteomic analysis of a meningococcal outer membrane vesicle vaccine prepared from the group B strain NZ98\/254","volume":"6","author":"Vipond","year":"2006","journal-title":"Proteomics"},{"key":"10.1016\/j.vaccine.2018.06.038_b0065","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1002\/pmic.200500164","article-title":"Outer membrane vesicles from group B Neisseria meningitidis Deltagna33 mutant: proteomic and immunological comparison with detergent-derived outer membrane vesicles","volume":"6","author":"Ferrari","year":"2006","journal-title":"Proteomics"},{"key":"10.1016\/j.vaccine.2018.06.038_b0070","doi-asserted-by":"crossref","first-page":"4725","DOI":"10.1128\/JB.181.16.4725-4733.1999","article-title":"Structures of gram-negative cell walls and their derived membrane vesicles","volume":"181","author":"Beveridge","year":"1999","journal-title":"J Bacteriol"},{"key":"10.1016\/j.vaccine.2018.06.038_b0075","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1574-6968.1998.tb13049.x","article-title":"On the origin of membrane vesicles in gram-negative bacteria","volume":"163","author":"Zhou","year":"1998","journal-title":"FEMS Microbiol Lett"},{"key":"10.1016\/j.vaccine.2018.06.038_b0080","doi-asserted-by":"crossref","first-page":"169","DOI":"10.14573\/altex.2013.2.169","article-title":"Evidence for the detection of non-endotoxin pyrogens by the whole blood monocyte activation test","volume":"30","author":"Hasiwa","year":"2013","journal-title":"ALTEX"},{"key":"10.1016\/j.vaccine.2018.06.038_b0085","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1128\/jcm.20.3.323-329.1984","article-title":"Human leukocytic pyrogen test for detection of pyrogenic material in growth hormone produced by recombinant Escherichia coli","volume":"20","author":"Dinarello","year":"1984","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2018.06.038_b0090","doi-asserted-by":"crossref","first-page":"S178","DOI":"10.1086\/317513","article-title":"Circulating cytokines as mediators of fever","volume":"31","author":"Netea","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2018.06.038_b0095","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jim.2004.03.002","article-title":"Monocyte activation test for pro-inflammatory and pyrogenic contaminants of parenteral drugs: test design and data analysis","volume":"288","author":"Gaines Das","year":"2004","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2018.06.038_b0100","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0022-1759(02)00519-7","article-title":"A rapid 'one-plate' in vitro test for pyrogens","volume":"274","author":"Poole","year":"2003","journal-title":"J Immunol Methods."},{"key":"10.1016\/j.vaccine.2018.06.038_b0105","doi-asserted-by":"crossref","first-page":"130-","DOI":"10.1016\/S0140-6736(88)90338-8","article-title":"Detection of pyrogen by cytokine release","volume":"1","author":"Poole","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.06.038_b0110","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jim.2004.08.019","article-title":"Cryopreservation of human whole blood for pyrogenicity testing","volume":"294","author":"Schindler","year":"2004","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2018.06.038_b0115","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.2042-7158.1991.tb03540.x","article-title":"Assay of pyrogens by interleukin-6 release from monocytic cell lines","volume":"43","author":"Taktak","year":"1991","journal-title":"J Pharm Pharmacol."},{"key":"10.1016\/j.vaccine.2018.06.038_b0120","first-page":"73","article-title":"Replacement, reduction and refinement","volume":"19","author":"Flecknell","year":"2002","journal-title":"ALTEX"},{"key":"10.1016\/j.vaccine.2018.06.038_b0125","unstructured":"The European Parliament and the Council of the European Union. Directive 2010\/63\/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes Legislation for the protection of animals used for scientific purposes. In: Commission E, editor. 2010\/63\/EU. Official Journal of the European Union: European Commission; 20.10.2010. p. 33\u201379."},{"key":"10.1016\/j.vaccine.2018.06.038_b0130","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S2352-4642(18)30103-2","article-title":"Safety of multicomponent meningococcal group B vaccine (4CMenB) in routine infant immunisation in the UK: a prospective surveillance study","volume":"2","author":"Bryan","year":"2018","journal-title":"Lancet Child & Adolescent Health"},{"key":"10.1016\/j.vaccine.2018.06.038_b0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2009.10.013","article-title":"Improved in vitro methods to predict the in vivo toxicity in man of therapeutic monoclonal antibodies including TGN1412","volume":"352","author":"Findlay","year":"2010","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2018.06.038_b0140","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jim.2015.12.001","article-title":"Leukoreduction system chambers provide a valuable source of functional monocytes for the monocyte activation test by comparison with internationally validated methods","volume":"428","author":"Nordgren","year":"2016","journal-title":"J Immunol Methods."},{"key":"10.1016\/j.vaccine.2018.06.038_b0145","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jama.2012.85","article-title":"Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial","volume":"307","author":"Gossger","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2018.06.038_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(12)61961-8","article-title":"Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials","author":"Vesikari","year":"2013","journal-title":"Lancet"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18308661?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18308661?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:33:38Z","timestamp":1759401218000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18308661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":30,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0264410X18308661"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.06.038","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and validation of a monocyte activation test for the control\/safety testing of an OMV-based meningococcal B vaccine","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.06.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2018 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}